Respiratory Inhalers Market Future Technological Advancement with Top Players AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim, Cipla, GlaxoSmithKline, Koninklijke Philips

Respiratory diseases such as bronchitis, asthma, allergic rhinitis, pneumonia and sinusitis can significantly curtail the physical activities of the individual. The symptoms associated with both mild and severe manifestations of these respiratory conditions include coughing, wheezing, chest pain, respiratory distress, shortness of breath, congestion, and even death in severe cases. These conditions lead to substantial morbidity and causes large cost of burden to the society. Increasing air pollution can severely affect respiratory health of children as well as adults. Various studies conducted have shown the ill effects of air pollution that can exacerbate existing respiratory conditions such as asthma, COPD, and upper airway allergies. According to the Forum of International Respiratory Societies, in 2013, young children and infants were especially susceptible to respiratory diseases. Around 9.0 million children under the age of 5 years die per year and the common thing in them is the presence of lung diseases. Increase in evidences through such studies suggests that the exposure to certain type of air pollutants contributes to the onset of asthma. However, studies related to the exacerbation of pre-acquired and existing asthma are more prevalent as they provide favorable conditions to study.

The global respiratory inhalers market was valued at US$ 27,424.4 million in 2016 and is expected to witness a robust CAGR of 5.7% over the forecast period (2017-2025).

According to Next Breath, LLC, in 2013, in the U.S for asthma/COPD there were no generic inhalers available, which includes both categories of standard asthma treatment such as controller medications for long-term prevention and rescue medication for quick relief. The above inhalers medicine average cost ranges between US$ 35 and US$ 300, rendering the treatment expensive for both consumers that are insured as well as uninsured. Furthermore, there are various many pressurized metered dose inhalers (pMDIs) that are approaching towards the patent expiration, and due to the lack of a document from the U.S. Food and Drug Administration (FDA) for guidance, generic companies are reluctant to spend in new product development, which finally might not be acceptable to the agency. According to Forum of International Respiratory Societies, in 2013, it has been estimated that around 235 million people suffered from asthma and more than 200 million people were affected from chronic obstructive pulmonary disease (COPD), and around 65 million endure mild-to-severe COPD. Also, around 2 billion people were exposed to the toxic effects of biomass fuel consumption and air pollution and by tobacco smoke.

Request A Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/227

Growth in respiratory inhalers market on the backdrop of product launches and Technological Advancements

For instance:

In 2017, Cipla launched Synchrobreathe, a revolutionary inhaler that will bring great relief to millions of South Africans with obstructive airway diseases (OAD) such as asthma

Smart inhalers have embedded sensors with bluetooth technology. These devices also come up with touchscreens, audio visual medication reminders along with additional advantages such as mobile application connectivity, customized user interface options, real time analysis through cloud based portals through researchers and clinicians. In September, 2017, Adherium received approval from the U.S Food and Drug Administration (FDA) for its SmartTouch inhaler monitoring device to be used with AstraZeneca’s Symbiocort aerosol inhaler.

In October, 2017, United Therapeutics Corporation received U.S. FDA approval for a new inhalation device TD-300/A, for the use with Tyvaso (treprostinil) inhalation solution to treat patient with pulmonary arterial hypertension. The device aid patient compliance and provides ease of use. It will also reduce the rate of therapy discontinuation associated with the current nebulizer.

In September, GlaxoSmithKline plc, received approval for Trelegy Ellipta. Trelegy Ellipta, is the first once-daily use inhaler triple therapy (i.e. combination of 3 active molecules in a single inhaler) for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

In April, 2016, AstraZeneca received approval for Bevespi Aerosphere, the first product which uses AstraZeneca’s Co-Suspension Technology. The technology enables more than one medicine delivery from a single MDI.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/227

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.